Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvelestat - Mereo BioPharma

Drug Profile

Alvelestat - Mereo BioPharma

Alternative Names: AZD-9668; MPH-966

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Allegheny Singer Research Institute; AstraZeneca; Mereo BioPharma; National Cancer Institute (USA)
  • Class Amides; Anti-infectives; Anti-inflammatories; Antibronchitics; Antifibrotics; Antihyperglycaemics; Bronchodilators; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alpha 1-antitrypsin deficiency

Highest Development Phases

  • Phase II Alpha 1-antitrypsin deficiency; Type 2 diabetes mellitus
  • Phase I/II Bronchiolitis obliterans; COVID-19 respiratory infection
  • Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 18 Jan 2024 AstraZeneca in collaboration with Mereo Biopharma plans to launch alvelestat for Alpha 1-antitrypsin deficiency in USA (PO), by 2028
  • 01 Dec 2023 University of Alabama at Birmingham completes a phase II trial for Alpha 1-antitrypsin deficiency in USA (NCT03679598)
  • 23 Oct 2023 Efficacy and adverse events data from a phase II trial for Alpha 1-antitrypsin deficiency released by Mereo Biopharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top